Capital Analysts LLC’s Dianthus Therapeutics DNTH Stock Holding History

Capital Analysts LLC’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$176	Buy	+2	New	+$208	﹤0.01%	1697

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Capital Analysts LLC's DNTH Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Dianthus Therapeutics (DNTH) in Q3 2026: 2 shares worth $176. The stake represents ﹤0.01% of the portfolio and ranks #1697 among its holdings.

188 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Capital Analysts LLC held 2 shares of Dianthus Therapeutics worth $176 as of Q3 2026.
Dianthus Therapeutics was a new Capital Analysts LLC position in Q3 2026.
Dianthus Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #1697 holding.
188 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.